Andrew Senn serves as President of the Cardio & Vascular segment at Integer Holdings Corporation, a global leader in the design, development, and manufacturing of medical device components and assemblies. With more than 25 years of experience in the medical technology industry, Andrew began his career as a design engineer at Guidant Corporation, advancing through roles in product development, operations, and commercial leadership at Medtronic and Abbott Vascular. His early expertise in cardiovascular device engineering laid the foundation for his strategic acumen, earning him recognition for launching multiple blockbuster products that improved patient outcomes in rhythm management and structural heart interventions. Throughout his career, Andrew has driven transformative achievements, including leading a $500 million revenue turnaround at a previous employer through operational optimization and supply chain innovation. He spearheaded the integration of key acquisitions, enhancing manufacturing capabilities and regulatory compliance across FDA, CE Mark, and ISO standards. His commitment to innovation has resulted in over 50 patents in vascular access and cardiac delivery systems, positioning his teams at the forefront of minimally invasive therapies. In his current role at Integer, Andrew oversees a dynamic portfolio serving major OEMs in electrophysiology, cardiac rhythm management, and peripheral vascular markets. He champions growth strategies that leverage Integer's advanced technologies, such as precision machining and bioactive coatings, to deliver high-volume, complex assemblies. Under his leadership, the Cardio & Vascular segment has achieved double-digit annual growth, solidifying Integer's reputation as an indispensable partner in advancing cardiovascular care worldwide.